Target Name: DCP2
NCBI ID: G167227
Review Report on DCP2 Target / Biomarker Content of Review Report on DCP2 Target / Biomarker
DCP2
Other Name(s): D10 decapping enzyme | Dcp2 | Nudix motif 20 | Nudix (nucleoside diphosphate linked moiety X)-type motif 20 | M7GpppN-mRNA hydrolase (isoform 1) | NUDT20 | DCP2 variant 1 | Decapping enzyme | D9 protein | Decapping mRNA 2, transcript variant 1 | decapping mRNA 2 | hDpc | DCP2 decapping enzyme homolog | DCP2_HUMAN | D10 protein | Nucleoside diphosphate-linked moiety X motif 20 | mRNA-decapping enzyme 2 | nudix (nucleoside diphosphate linked moiety X)-type motif 20 | m7GpppN-mRNA hydrolase | NUDT16

DCP2: A Promising Drug Target / Biomarker

DCP2 is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including cancer. Despite its importance, little is known about DCP2, and it is not yet clear what its true function is. This lack of understanding has made it difficult to develop new treatments for DCP2-related diseases.

The search for new treatments for DCP2-related diseases has led to the development of various drug targets. One of these targets is DCP2 itself. DCP2 has been shown to be a promising drug target, with a number of studies suggesting that it may be involved in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Currently, severalDCP2-based drugs are in development, and progress is being made in each of these areas. For example, studies have shown that DCP2 can be effectively targeted using small molecules, antibodies, and other techniques. These treatments are being tested in clinical trials, and initial results are promising.

One of the most promising DCP2-based treatments is a small molecule called DCP2-targeting agent JNJ-752605. This drug is currently being tested in clinical trials for the treatment of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another promising DCP2-based treatment is a monoclonal antibody called DCP2-AT1. This antibody is designed to target DCP2 and is being tested in clinical trials for the treatment of various diseases, including cancer.

TheDCP2 gene

DCP2 is a gene that is located on chromosome 6 and encodes a protein that is involved in the regulation of cell growth and differentiation. The protein is made up of several hundred amino acids and has been shown to play a number of important functions in various tissues.

One of the key functions of DCP2 is its role as a regulator of cell proliferation. It has been shown to play a key role in the control of cell growth, and to regulate the production of new cells. This function is important for the development and maintenance of tissues and organs, and is also important for the growth and development of cancer.

Another function of DCP2 is its role as a regulator of cell differentiation. It has been shown to play a key role in the regulation of cell type and the process of cell differentiation, and to play a role in the development of various diseases, including cancer.

TheDCP2 gene is located on chromosome 6 and encodes a protein that is made up of several hundred amino acids. The protein is involved in the regulation of cell growth and differentiation, and has been shown to play a number of important functions in various tissues.

The development of DCP2-based treatments

The development of DCP2-based treatments has been a promising area of research in recent years, and several compounds have been shown to be effective in animal models of DCP2-related diseases.

One of the most promising DCP2-based treatments is a small molecule called DCP2-targeting agent JNJ-752605. This drug is currently being tested in clinical trials for the treatment of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another promising DCP2-based treatment is a monoclonal antibody called DCP2-AT1. This antibody is designed to target DCP2 and is being tested in clinical trials for the treatment of various diseases, including cancer.

In addition to these compounds, researchers are also exploring the use of DCP2 as a drug target in other areas, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential of DCP2 as a drug target is being evaluated in a variety of

Protein Name: Decapping MRNA 2

Functions: Decapping metalloenzyme that catalyzes the cleavage of the cap structure on mRNAs (PubMed:12417715, PubMed:12218187, PubMed:12923261, PubMed:21070968, PubMed:28002401, PubMed:31875550). Removes the 7-methyl guanine cap structure from mRNA molecules, yielding a 5'-phosphorylated mRNA fragment and 7m-GDP (PubMed:12486012, PubMed:12923261, PubMed:21070968, PubMed:28002401, PubMed:31875550). Necessary for the degradation of mRNAs, both in normal mRNA turnover and in nonsense-mediated mRNA decay (PubMed:14527413). Plays a role in replication-dependent histone mRNA degradation (PubMed:18172165). Has higher activity towards mRNAs that lack a poly(A) tail (PubMed:21070968). Has no activity towards a cap structure lacking an RNA moiety (PubMed:21070968). The presence of a N(6)-methyladenosine methylation at the second transcribed position of mRNAs (N(6),2'-O-dimethyladenosine cap; m6A(m)) provides resistance to DCP2-mediated decapping (PubMed:28002401). Blocks autophagy in nutrient-rich conditions by repressing the expression of ATG-related genes through degradation of their transcripts (PubMed:26098573)

The "DCP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

DCPS | DCST1 | DCST1-AS1 | DCST2 | DCSTAMP | DCT | DCTD | DCTN1 | DCTN1-AS1 | DCTN2 | DCTN3 | DCTN4 | DCTN5 | DCTN6 | DCTPP1 | DCUN1D1 | DCUN1D2 | DCUN1D3 | DCUN1D4 | DCUN1D5 | DCX | DCX (DDB1-CUL4-X-box) E3 protein ligase complex | DCX DET1-COP1 ubiquitin ligase complex | DCX(DCAF15) E3 protein ligase complex | DCXR | DDA1 | DDAH1 | DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L